Avandia Search Engine Blog

An Attorney for You helping Patients Affected by New Potential Avandia Recall Lawsuits (PR.com)

2010-03-09T17:20:00.001-06:00

Senate study says the drug maker, GlaxoSmithKline knew that heart attacks were probable tied to Avandia. [PR.com]

Cedars-Sinai Heart Institute Cardiologist Sanjay Kaul, M.D. Co-Authors Statement On Safety Of Diabetes Drugs (Medical News Today)

2010-03-04T17:20:00.001-06:00

A Cedars-Sinai Heart Institute cardiologist co-authored the joint science advisory issued by the American Heart Association and the American College of Cardiology that calls for close monitoring of patients taking certain blood sugar-lowering drugs. Sanjay Kaul, M.D. co-authored the advisory about drugs called thiazolidinediones (TZDs) such as pioglitazone (Actos) or Rosiglitazone (Avandia)...

Diabetic drug warning (The New Straits Times)

2010-03-02T05:20:00.001-06:00

KUALA LUMPUR: Thirty-three Malaysians have filed complaints with the Health Ministry about adverse effects after taking an antidiabetic agent, rosiglitazone, also known as Avandia.

Whatâs Your Guidance for People Taking Avandia? (US News & World Report)

2010-02-28T05:20:00.001-06:00

Some perspective on the diabetes drug, as the FDA prepares to consider its heart risks

GlaxoSmithKline responds to Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia (News-Medical-Net)

2010-02-25T05:20:00.001-06:00

Today, GlaxoSmithKline responded to the recently released Senate Committee on Finance's January 2010 "Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia" (the "Staff Report").

Senators challenge safety of GlaxoSmithKlein's Avandia (CNN Money)

2010-02-21T17:20:00.001-06:00

The diabetes drug Avandia is linked with tens of thousands of heart attacks, and drugmaker GlaxoSmithKline knew of the risks for years but worked to keep them from the public, a Senate committee report released Saturday says.

Don't Ignore This Potential Blockbuster (The Motley Fool)

2010-02-14T05:20:00.001-06:00

Five trials later, Roche's taspoglutide seems like a winner.

Avandia Information and Support Center Announces Launch of Avandia-Injury-Lawyer.com (PRWeb via Yahoo! News)

2010-02-09T05:20:00.001-06:00

The Avandia Information and Support Center is proudly announcing the launch of Avandia-Injury-Lawyer.com, a brand new website whose aim is to provide vital information regarding the type-2 diabetes prescription drug Avandia.

New Scientific Studies Show Further Evidence of Avandia Dangers (PRWeb)

2010-02-04T05:20:00.001-06:00

Two independent studies document serious medical risks associated with use of popular GlaxoSmithKline diabetes drug (PRWeb Feb 4, 2010) Read the full story at http://www.prweb.com/releases/2010/02/prweb3563424.htm

Research could help in developing more specific treatments for Type 2 diabetes (News-Medical-Net)

2010-02-02T05:20:00.001-06:00

New research on Type 2 diabetes by Trinity College Dublin researchers could benefit young adults (aged 18-25 years) with the condition. The research led by Professor John Nolan of Trinity College Dublin and St James's Hospital, Dublin, has just been published online in the leading international journal, Diabetes Care.

Free Legal Consultation for Sudden Unintended Acceleration Incidences in Toyota/Lexus Recalled Cars Now Offered by ... (PRWeb via Yahoo! News)

2010-01-31T05:20:00.001-06:00

Personal injury lawyers, Ennis & Ennis, P.A., are now providing free legal consultation to individuals who have experienced sudden unintended acceleration. All consultations are free, confidential and are available nationwide.

GSK Conducting PGx Trials for Newly Approved Tykerb; Monogram eTag Assays May Play Role (GenomeWeb News)

2010-01-28T05:20:00.001-06:00

GlaxoSmithKline is hoping that pharmacogenomic studies of its newly approved targeted breast cancer drug Tykerb will help identify patients with other solid tumors likely to respond to the drug.

Drug Safety Whistleblower Wants to Fix FDA. GTO Says, Good Luck! (GenomeWeb News)

2010-01-24T05:20:00.001-06:00

The International Herald Tribune profiles Steven Nissen , the Cleveland Clinic scientist best known for his early warnings about the safety of Vioxx, long before the drug was taken off the market.

Avandia Linked to Heart Attacks, Liver Failure, and More

2009-10-15T16:20:00.002-06:00

The diabetes drug Avandia has been linked to so many health problems that some have questioned whether or not it should be on the market at all. In November 2007, a warning detailing Avandia's association with myocardial ischemia was added to the drug's boxed warning. The warning followed an analysis of 42 clinical trails published [...]

The Diabetes Drug Avandia has been Linked to Heart Attacks

2009-10-11T16:20:00.003-06:00

The Mulligan Law Firm is currently investigating injury claims involving Avandia's possible role in heart attacks and heart disease.

Amylin and Biocon collaborate to develop a peptide therapeutic for treating diabetes

2009-09-24T04:20:00.002-06:00

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Biocon, Limited (NSE: BIOCON) announced today that they have entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs. Research will ...

Avoid Diabetes Drugs

2009-09-03T04:20:00.002-06:00

In a four-year study, the popular Mediterranean-style diet helped keep type 2 diabetes patients off blood-sugar-controlling medications.

Diabetes drug linked to heart failure risk

2009-08-25T16:20:00.002-06:00

Canadian scientists say they have discovered rosiglitazone (Avandia) a type 2 diabetes drug, might be linked with increased risk of heart failure and death. The scientists from the University of Toronto and the Sunnybrook Health Sciences Center in Toronto, said the linkage was found among older patients, compared to a similar drug, pioglitazone (Actos). The scientists utilised prescription records ...

Still Prescribing Killer Diabetes Drug?

2009-08-23T04:20:00.003-06:00

Stop prescribing killer diabetes drug, scientists warn (Guardian Unlimited)
Rosiglitazone, brand name Avandia, has higher rates of heart failure and death than similar alternative Scientists say doctors should stop prescribing a commonly used diabetes drug, after studies show that it is linked to higher rates of heart failure and death than a similar alternative. David Juurlink, a Toronto-based pharmacologist and lead author of a paper published online today by the ...

Avandia Heart Failure Risk More Than Actos

2009-08-20T16:20:00.002-06:00

Avandia Raises Heart Failure Risk More Than Actos (MedicineNet.com)
Title: Avandia Raises Heart Failure Risk More Than Actos Category: Health News Created: 8/19/2009 8:10:00 AM Last Editorial Review: 8/19/2009

FDA approves diabetes drug from two manufacturers

2009-08-02T16:20:00.002-06:00

FDA approves diabetes drug from two area manufacturers (Worcester Telegram & Gazette)
Bristol-Myers Squibb Co. and AstraZeneca Plc won U.S. approval for a new diabetes treatment to compete with Merck & Co.'s Januvia.

Glaxo profits up

2009-07-23T10:03:00.002-06:00

GlaxoSmithKline, the world's second largest drug maker by revenues, posted an 11 percent rise in second quarter profit on Wednesday after strong pharmaceutical sales in emerging markets helped offset the impact of generic competition in the United States.

Glaxo profits up 11 percent on emerging markets

2009-07-22T10:03:00.002-06:00

Alzheimer's Disease Conference (ICAD) Highlights Promise and Setbacks

2009-07-20T10:03:00.002-06:00

RESEARCH TRIANGLE PARK, NC--(Marketwire - July 20, 2009) - As is often the case, recent news regarding potential treatments for Alzheimer's disease contains both promise and disappointment. The International Conference on Alzheimer's Disease (ICAD) draws attention to the leading science behind the fight against the disease. A major announcement preceded the conference, held in Vienna, Austria, ...

Drug Toxicity Assay Kits Increase Drug Development Efficiency

2009-05-31T23:21:00.000-06:00

Bioo Scientific's Toxicity Assay Kits Increase the Efficiency of Drug Development

Bioo Scientific announced the launch of the MaxDiscoveryT Toxicity Assay Kits for the monitoring of toxic effects in in vivo preclinical studies.

Austin, TX, May 31, 2009 -- Since toxicity is one of the leading causes of drug failures, measuring preclinical toxicity is a critical drug development function. Accurate in vivo toxicity assays are essential to lowering attrition and increasing efficiency in drug development.

Bioo Scientific announced today the launch of their MaxDiscoveryT Toxicity Assay Kits. These kits monitor in vivo toxicity by measuring liver and heart function in serum samples. They provide simple, convenient, colorimetric determination of well-characterized functional markers of for liver and heart. They are ideal tools to monitor toxic effects caused by administration of siRNA, DNA plasmids, transfection agents or other therapeutic treatments during preclinical studies. The assays can be used in a range of mammals, including mice and rats, providing a powerful tool to assess and reduce the toxicity of drugs formulations and to improve drug delivery methods.

According to Dr Joe Krebs, Director of Protein Chemistry and Engineering at Bioo Scientific, "MaxDiscoveryT Toxicity kits are designed to provide researchers with rapid, cost-effective tools required to address the escalating challenges of drug development in today's competitive landscape."

Assays are available for alanine transaminase, aspartate transminase, alkaline phosphatase, lactate dehydrogenase, cholesterol, and creatine kinase.

About Bioo Scientific
Bioo Scientific Corporation is a global biotechnology tools company, headquartered in Austin, Texas. Bioo Scientific provides innovative products and services to academic researchers, pharmaceutical and biotechnology companies, molecular diagnostics laboratories, and customers who perform food and feed safety analysis.

Contact Information
Bioo Scientific
Dawn Obermoeller
512-301-4094
dawn@redbridgemarketing.com
www.biooscientific.com